Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophy

Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophy

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for geographic atrophy.The post Boehringer Ingelheim begins Phase II trial of BI 1584862 for geographic atrophy appeared first on Clinical Trials Arena.

Boehringer Ingelheim and Datavant Expand Partnership to Enhance Real-World Evidence through Advanced Data Technologies

Boehringer Ingelheim, a leading German pharmaceutical company, has strengthened its partnership with US-based Datavant to expand its real-world evidence (RWE) initiatives. By leveraging Datavant’s privacy-preserving tokenization and data connectivity technologies, Boehringer Ingelheim seeks to enhance the clinical development and launch strategies for 75 additional clinical trials and new molecular entities (NMEs). Utilizing Datavant Connect pow…